Accéder au contenu
Merck

Optical imaging of breast cancer using hemodynamic changes induced by valsalva maneuver.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin (2013-03-16)
N F Schreiter, N Volkwein, P Schneider, M H Maurer, S Piper, C Schmitz, A Poellinger
RÉSUMÉ

To investigate whether changes in hemodynamics induced by Valsalva maneuver can be exploited for detecting and characterizing breast lesions by optical mammography. 30 women underwent optical imaging of the breast using a DYNOT 232 system and performing Valsalva maneuvers prior to biopsy. Changes in light absorption due to changes in oxyhemoglobin and deoxyhemoglobin concentrations were recorded volumetrically and in a time-resolved manner. The parameters full width at half maximum (FWHM), time to ten (TTT), and peak amplitude (PA) of the reconstructed concentration time curves yielded color-coded maps of the breast which were separately evaluated by two experienced readers for detection rate, degree of visibility, and detection of additional lesions. ROC analysis was performed with the evaluation results. 10 patients were excluded from analysis due to artifacts or inadequately performed Valsalva maneuver. The resulting 20 patients showed a clear increase in oxygenated and deoxygenated hemoglobin concentration after the onset of the Valsalva maneuver. ROC analysis yielded AUC values (0.393 - 0.779) that did not differ from random probabilities. The highest AUC values were obtained for FWHM (AUC: 0.779, detection rates [60 - 70 %], identification of additional lesions [55 - 70 %]). PA analysis had the highest detection rate (70 - 90 %) but also the highest identification of false-positive additional lesions (80 - 90 %). The concordance rates of the two readers for malignant lesions were satisfactory (0.524 - 1.0). Our study revealed susceptibility to artifacts and a large number of false-positive additional lesions, suggesting that the evaluation of hemodynamic changes after Valsalva maneuver by optical imaging is not a promising method.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Hemoglobin human, lyophilized powder
Sigma-Aldrich
Hemoglobin from bovine blood, lyophilized powder
Sigma-Aldrich
Hemoglobin from bovine blood, suitable for protease substrate, substrate powder
Sigma-Aldrich
Hemoglobin porcine, lyophilized powder
Sigma-Aldrich
Hemoglobin from bovine blood, dried erythrocytes
Millipore
Hemoglobin from bovine blood, suitable for microbiology